Attempt to enhance resistance to infection in 6-mercaptopurine treated mice by lysozyme administration and immunization with Escherichia coli O86 antigen.
Long-term immunosuppressive therapy of mice with 6-mercaptopurine (6-MP) for 2 and/or 3 weeks results in partial lethality, decrease of total leukocyte count, of serum lysozyme level and in bacteremia. The adverse effect of 6-MP treatment could not be prevented by lysozyme administration; immunization with Escherichia coli O86 antigen further increased the lethality of 6-MP in mice. The results stress the potential danger of immunization with bacterial antigens during immunosuppressive therapy.
D000818:Animals; D000942:Antigens, Bacterial / Q000009:adverse effects; D001424:Bacterial Infections / Q000276:immunology*; D001769:Blood / Q000382:microbiology; D001835:Body Weight; D004755:Enterobacteriaceae / Q000302:isolation & purification; D004926:Escherichia coli / Q000276:immunology* / Q000302:isolation & purification; D005260:Female; D007114:Immunization; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007274:Injections, Intraperitoneal; D007958:Leukocyte Count; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects*; D051379:Mice; D009113:Muramidase / Q000097:blood / Q000627:therapeutic use*; D011511:Proteus / Q000302:isolation & purification
D000942:Antigens, Bacterial; D007166:Immunosuppressive Agents; D015122:Mercaptopurine; D009113:Muramidase